-DOCSTART- -X- O
Inflammation -X- _ O
is -X- _ O
an -X- _ O
essential -X- _ O
host -X- _ O
defence -X- _ O
against -X- _ O
infection -X- _ O
, -X- _ O
but -X- _ O
can -X- _ O
be -X- _ O
damaging -X- _ O
when -X- _ O
excessive. -X- _ O
Resolution -X- _ O
of -X- _ O
inflammation -X- _ O
is -X- _ O
an -X- _ O
active -X- _ O
process -X- _ O
, -X- _ O
and -X- _ O
the -X- _ O
pro-resolution -X- _ B-Patient
effects -X- _ I-Patient
of -X- _ I-Patient
lipoxins -X- _ I-Patient
, -X- _ I-Patient
resolvins -X- _ I-Patient
and -X- _ I-Patient
protectins -X- _ I-Patient
have -X- _ O
received -X- _ O
significant -X- _ O
interest. -X- _ O
Here -X- _ O
, -X- _ O
we -X- _ O
review -X- _ O
emerging -X- _ O
data -X- _ O
on -X- _ O
the -X- _ O
role -X- _ O
of -X- _ O
these -X- _ O
lipid -X- _ B-Patient
mediators -X- _ I-Patient
in -X- _ I-Patient
infectious -X- _ I-Patient
disease. -X- _ I-Patient
Lipoxins -X- _ B-Outcome
influence -X- _ I-Outcome
host -X- _ I-Outcome
control -X- _ I-Outcome
of -X- _ I-Outcome
Mycobacterium -X- _ I-Outcome
tuberculosis -X- _ I-Outcome
, -X- _ I-Outcome
Toxoplasma -X- _ I-Outcome
gondii -X- _ I-Outcome
, -X- _ I-Outcome
Trypanosoma -X- _ I-Outcome
cruzi -X- _ I-Outcome
and -X- _ I-Outcome
Plasmodium -X- _ I-Outcome
berghei -X- _ I-Outcome
cerebral -X- _ I-Outcome
malaria -X- _ I-Outcome
in -X- _ I-Outcome
mice. -X- _ I-Outcome
Their -X- _ I-Outcome
effects -X- _ I-Outcome
are -X- _ I-Outcome
protective -X- _ I-Outcome
in -X- _ I-Outcome
toxoplasmosis -X- _ I-Outcome
, -X- _ I-Outcome
T. -X- _ I-Outcome
cruzi -X- _ I-Outcome
infection -X- _ I-Outcome
and -X- _ I-Outcome
cerebral -X- _ I-Outcome
malaria -X- _ I-Outcome
but -X- _ I-Outcome
detrimental -X- _ I-Outcome
in -X- _ I-Outcome
tuberculosis -X- _ I-Outcome
; -X- _ I-Outcome
related -X- _ I-Outcome
to -X- _ I-Outcome
the -X- _ I-Outcome
balance -X- _ I-Outcome
between -X- _ I-Outcome
pathogen-control -X- _ I-Outcome
and -X- _ I-Outcome
excessive -X- _ I-Outcome
immune -X- _ I-Outcome
response. -X- _ I-Outcome
Topical -X- _ I-Outcome
lipoxin -X- _ I-Outcome
abrogates -X- _ I-Outcome
the -X- _ I-Outcome
tissue -X- _ I-Outcome
damage -X- _ I-Outcome
seen -X- _ I-Outcome
in -X- _ I-Outcome
a -X- _ I-Outcome
rabbit -X- _ I-Outcome
model -X- _ I-Outcome
of -X- _ I-Outcome
Porphyromonas -X- _ I-Outcome
gingivalis -X- _ I-Outcome
periodontitis. -X- _ I-Outcome
The -X- _ O
increased -X- _ O
virulence -X- _ O
of -X- _ O
H5N1 -X- _ O
influenza -X- _ O
A -X- _ O
virus -X- _ O
in -X- _ O
mice -X- _ O
correlates -X- _ O
with -X- _ O
reduced -X- _ O
expression -X- _ O
of -X- _ O
SOCS2 -X- _ O
, -X- _ O
required -X- _ O
to -X- _ O
mediate -X- _ O
the -X- _ O
effects -X- _ O
of -X- _ O
lipoxin. -X- _ O
Mice -X- _ B-Outcome
unable -X- _ I-Outcome
to -X- _ I-Outcome
synthesize -X- _ I-Outcome
lipoxin -X- _ I-Outcome
suffer -X- _ I-Outcome
increased -X- _ I-Outcome
lung -X- _ I-Outcome
pathology -X- _ I-Outcome
during -X- _ I-Outcome
respiratory -X- _ I-Outcome
syncytial -X- _ I-Outcome
virus -X- _ I-Outcome
infection. -X- _ I-Outcome
Protectin -X- _ I-Outcome
suppresses -X- _ I-Outcome
influenza -X- _ I-Outcome
A -X- _ I-Outcome
virus -X- _ I-Outcome
replication -X- _ I-Outcome
in -X- _ I-Outcome
vitro -X- _ I-Outcome
and -X- _ I-Outcome
increases -X- _ I-Outcome
survival -X- _ I-Outcome
in -X- _ I-Outcome
a -X- _ I-Outcome
mouse -X- _ I-Outcome
model -X- _ I-Outcome
of -X- _ I-Outcome
severe -X- _ I-Outcome
influenza -X- _ I-Outcome
infection. -X- _ I-Outcome
Resolvins -X- _ I-Outcome
were -X- _ I-Outcome
investigated -X- _ I-Outcome
in -X- _ I-Outcome
a -X- _ I-Outcome
number -X- _ I-Outcome
of -X- _ I-Outcome
animal -X- _ I-Outcome
models -X- _ I-Outcome
of -X- _ I-Outcome
systemic -X- _ I-Outcome
bacterial -X- _ I-Outcome
infection -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
were -X- _ I-Outcome
found -X- _ I-Outcome
to -X- _ I-Outcome
enhance -X- _ I-Outcome
phagocytic -X- _ I-Outcome
clearance -X- _ I-Outcome
of -X- _ I-Outcome
bacteria -X- _ I-Outcome
, -X- _ I-Outcome
reduce -X- _ I-Outcome
inflammation -X- _ I-Outcome
severity -X- _ I-Outcome
, -X- _ I-Outcome
promote -X- _ I-Outcome
neutrophil -X- _ I-Outcome
apoptosis -X- _ I-Outcome
, -X- _ I-Outcome
modulate -X- _ I-Outcome
neutrophil -X- _ I-Outcome
chemotaxis -X- _ I-Outcome
and -X- _ I-Outcome
importantly -X- _ I-Outcome
, -X- _ I-Outcome
reduce -X- _ I-Outcome
mortality. -X- _ I-Outcome
Interestingly -X- _ I-Outcome
, -X- _ I-Outcome
resolvin -X- _ I-Outcome
also -X- _ I-Outcome
enhances -X- _ I-Outcome
the -X- _ I-Outcome
antibacterial -X- _ I-Outcome
effect -X- _ I-Outcome
of -X- _ I-Outcome
ciprofloxacin -X- _ I-Outcome
and -X- _ I-Outcome
vancomycin. -X- _ I-Outcome
Topical -X- _ I-Outcome
resolvin -X- _ I-Outcome
application -X- _ I-Outcome
reduces -X- _ I-Outcome
the -X- _ I-Outcome
severity -X- _ I-Outcome
of -X- _ I-Outcome
herpes -X- _ I-Outcome
simplex -X- _ I-Outcome
virus -X- _ I-Outcome
ocular -X- _ I-Outcome
infection -X- _ I-Outcome
in -X- _ I-Outcome
mice. -X- _ I-Outcome
If -X- _ O
the -X- _ O
effects -X- _ O
of -X- _ O
these -X- _ O
mediators -X- _ O
translate -X- _ O
from -X- _ O
pre-clinical -X- _ O
studies -X- _ O
into -X- _ O
successful -X- _ O
clinical -X- _ O
trials -X- _ O
, -X- _ O
they -X- _ O
represent -X- _ O
promising -X- _ O
new -X- _ O
strategies -X- _ O
in -X- _ O
managing -X- _ O
infectious -X- _ O
disease -X- _ O
. -X- _ O

